Clinical trials: Rituximab, completed
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
The overall objective of this protocol is to improve the cure rate of relapsed precursor B-cell acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma.
- Trial name
- NCT01700946
- Testing
- dexamethasone, vincristine sulfate, rituximab
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- St. Jude Children's Research Hospital
Type 1 Diabetes Mellitus
Rituximab in New Onset Type 1 Diabetes
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks the insulin-producing beta cells in the pancreas.
- Trial name
- TN05 (NCT00279305)
- Testing
- Anti-CD20 (rituximab)
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 87 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.
This single arm study will evaluate the efficacy and safety of MabThera in patients with active rheumatoid arthritis whose current treatment with one or more TNF blocker had produced an inadequate response.
- Trial name
- NCT00424502
- Testing
- rituximab [MabThera/Rituxan], Methotrexate
- Where
- 3 sites in Hungary
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Lymphocytic Leukemia, Chronic
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)
This open-label, randomized, 3-arm study will evaluate the efficacy and safety of obinutuzumab (RO5072759) in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil alone in patients with…
- Trial name
- NCT01010061
- Testing
- obinutuzumab, rituximab, chlorambucil
- Where
- 261 sites in United States, Argentina and 24 more
- Volunteers
- 787 people
- Sponsor
- Hoffmann-La Roche
Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
This phase I/II trial studies the side effects and the best dose of veliparib when given together with bendamustine hydrochloride and rituximab and to see how well they work in treating patients with lymphoma, multiple myeloma…
- Conditions
- Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult Solid Neoplasm, Anaplastic Large Cell Lymphoma
- Trial name
- NCT01326702
- Testing
- Bendamustine Hydrochloride, Pharmacological Study, Rituximab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer
RATIONALE: Pentostatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and mitoxantrone, work in different ways to stop the growth…
- Trial name
- NCT00546377
- Testing
- filgrastim, pegfilgrastim, rituximab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Hodgkin Lymphoma, Hodgkin Disease
The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)
Participants with non-Hodgkin lymphoma (NHL) or Hodgkin disease (HD) will be assigned to one of 2 arms based on the immunophenotype of their lymphoma.
- Trial name
- NCT00444912
- Testing
- G-CSF plus plerixafor, rituximab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Genzyme, a Sanofi Company
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
This is an open-label, multicenter, phase 2 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma (NHL) (Part A).
- Conditions
- Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell
- Trial name
- NCT01421667
- Testing
- brentuximab vedotin, rituximab
- Where
- 34 sites in United States, Canada
- Volunteers
- 176 people
- Sponsor
- Seagen Inc.
Lymphoma, Leukemia
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
The goal of this clinical research study is to see if low intensity chemotherapy given together with the new drug 90Y Zevalin, followed by a transplant of blood or marrow stem cells from a donor can increase the length of…
- Trial name
- NCT00048737
- Testing
- Zevalin Radioimmunotherapy, Rituximab, Fludarabine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center
Rheumatoid Arthritis
GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®
The study objective is to identify potential safety risks of the transition from US-licensed Rituxan® or EU-approved MabThera® to GP2013 (proposed biosimilar product) as compared to continuous treatment with the originator…
- Trial name
- ASSIST-RT (NCT02514772)
- Testing
- GP2013 - A Proposed biosimilar rituximab, Originator rituximab - Rituxan ® or MabThera ®
- Where
- 65 sites in United States, Germany and 2 more
- Volunteers
- 107 people
- Sponsor
- Sandoz
Allogeneic Stem Cell Transplantation, Refractory Autoimmune Cytopenia(s)
Bortezomib to Treat Significant Complication of HSCT
The purpose of this trial is to study the safety and effectiveness of a drug called Bortezomib for the treatment of low blood cell counts after bone marrow transplant.
- Trial name
- Bortezomib (NCT01929980)
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Lymphoma, Large-Cell, Diffuse
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
This study is being conducted to compare the efficacy and safety of ofatumumab in addition to salvage chemotherapy versus rituximab in addition to salvage chemotherapy in CD20 positive DLBCL subjects relapsing, or with persistent…
- Trial name
- ORCHARRD (NCT01014208)
- Testing
- OFATUMUMAB + DHAP, RITUXIMAB + DHAP
- Where
- 173 sites in United States, Argentina and 24 more
- Volunteers
- 447 people
- Sponsor
- GlaxoSmithKline
Leukemia
A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL
RATIONALE: Monoclonal antibodies, such as alemtuzumab and rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00858117
- Testing
- Alemtuzumab, Rituximab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
Rheumatoid Arthritis
A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis
This study was designed to evaluate the safety of administering rituximab at a more rapid infusion rate in patients with moderate to severe rheumatoid arthritis who have had an inadequate response to biopharmaceuticals that treat…
- Trial name
- RATE-RA (NCT01382940)
- Testing
- rituximab, methotrexate, methylprednisolone
- Where
- 86 sites in United States
- Volunteers
- 351 people
- Sponsor
- Hoffmann-La Roche
Leukemia, Lymphoma
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
The goal of this clinical research study is to learn if adding Zevalin (ibritumomab tiuxetan) to low-intensity chemotherapy (the combination of rituximab, bendamustine, and fludarabine), followed by an allogeneic stem cell…
- Trial name
- NCT01490723
- Testing
- Rituximab, 111In Ibritumomab, Planar Scintigraphy Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Chronic Lymphocytic Leukemia
Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
The goal of this clinical research study is to learn if lirilumab in combination with rituximab can help to control either CLL or Small lymphocytic lymphoma (SLL). The safety of the drug combination will also be studied.
- Conditions
- Leukemia, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia
- Trial name
- NCT02481297
- Testing
- Lirilumab, Rituximab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
In this open-label single arm study the safety and efficacy of Mabthera will be evaluated in patients with active rheumatoid arthritis who have had an inadequate response to methotrexate.
- Trial name
- NCT01000610
- Testing
- rituximab [MabThera/Rituxan], methotrexate, methylprednisolone
- Where
- 4 sites in Tunisia
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Lymphoma
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
This single arm, multicenter study will evaluate the safety, efficacy and pharmacokinetic (PK) of subcutaneous (SC) rituximab in previously untreated participants with cluster of differentiation 20 positive (CD20+) DLBCL or FL.
- Trial name
- NCT01889069
- Testing
- Rituximab, Cyclophosphamide, Vincristine
- Where
- 39 sites in Italy
- Volunteers
- 159 people
- Sponsor
- Hoffmann-La Roche
Neoplasm Malignant
Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
Primary Objective: The purpose of this study was to determine the long term safety and tolerability of SAR245408 and SAR245409 as a monotherapy or as part of a combination regimen in participants who were benefiting from…
- Trial name
- NCT01587040
- Testing
- SAR245408, SAR245409
- Where
- 21 sites in United States, Belgium and 2 more
- Volunteers
- 61 people
- Sponsor
- Sanofi
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
This phase I/II trial is studying the side effects and best dose of vorinostat when given together with rituximab, ifosfamide, carboplatin, and etoposide and to see how well they work in treating patients with relapsed or…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Contiguous Stage II Mantle Cell Lymphoma
- Trial name
- NCT00601718
- Testing
- vorinostat, rituximab, ifosfamide
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Washington